NeuBase Therapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Accrued Expenses and Other Current Liabilities

12 Months Ended

Sep. 30, 2020

9. Accrued Expenses and Other Current Liabilities

The Company’s accrued expenses and other current liabilities consisted of the following:


	As of September 30,
	2020		2019
Accrued compensation and benefits	$	88,527	$	34,625
Accrued interest		3,707		10,830
Accrued professional fees		241,755		156,919
Accrued research and development		41,313		88,553
Other accrued expenses		180,581		114,672
Total	$	555,883	$	405,599